ATTAIN-J trial results

Adults in Japan meeting local obesity disease criteria, with or without type 2 diabetes.

Foundayo

Phase: Phase 3
Follow-up: 72 weeks
Randomised: 238
Sponsor: Eli Lilly
Publication: The Lancet Diabetes & Endocrinology · 2026

Double-blind, placebo-controlled. Treatment-regimen analysis. Orforglipron was studied as capsules.

Mean body weight change at 72 weeks

Orforglipron 6 mg−5.9%
Orforglipron 12 mg−8.7%
Orforglipron 36 mg−7.9%
Placebo−0.6%

Mean body weight change at 72 weeks
Trial arm	Result
Orforglipron 6 mg	−5.9%
Orforglipron 12 mg	−8.7%
Orforglipron 36 mg	−7.9%
Placebo	−0.6%

Participants who lost at least 5% of body weight at week 72
Trial arm	Result
Orforglipron 6 mg	45.6%
Orforglipron 12 mg	60.8%
Orforglipron 36 mg	58.8%
Placebo	15.2%

Safety. Adverse events were mostly mild or moderate gastrointestinal symptoms. Nausea and vomiting were the most common events leading to treatment discontinuation in the orforglipron groups.

Published paper PubMed abstract NCT05931380